TICKERNERD
Menu
SYKSYKHealthcare · Medical Devices

SYK Stock Forecast: Stryker Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$339
−0.55% on the day

The 28 Wall Street analysts covering Stryker Corp. hold a median 12-month price target of $381 — +12.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 13 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$130.8B
Ticker Nerd rank
74 / 100
Median analyst target
$381
Analysts covering
28
Total return, dividends reinvested
1W
+0.1%
1M
+9.0%
YTD
−3.0%
1Y
−9.5%
From 52W high
−13.1%
From 52W low
+20.4%
$282
$390
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SYK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Stryker Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
95
Quality
87
Issuance
87
Value
79
Growth
71
Accruals
57
Revisions
53
Momentum
37
Size
2

Volatility (95): The share price has been relatively steady.

Momentum (37): The shares have been drifting down relative to others.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SYK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SYK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$300$350$400$450Oct 25Jan 26Apr 26Jul 26SYKHigh $465Median $381Low $315

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says28 analysts
23 Buy5 Hold0 Sell
Low $315Median $381High $465

The green dot is the last close — the median target sits +12.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
3 Aug 2026CitizensMaintainsMarket Outperform$440 → $400
31 July 2026BTIGMaintainsBuy$371 → $358
31 July 2026JP MorganMaintainsOverweight$400 → $350
31 July 2026Piper SandlerMaintainsOverweight$420 → $390
31 July 2026RBC CapitalMaintainsOutperform$435 → $420
31 July 2026Truist SecuritiesMaintainsHold$330 → $340
28 July 2026UBSAssumesBuy$400
9 July 2026BMO CapitalInitiatesOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$355 → $350
6 July 2026Evercore ISI GroupMaintainsOutperform—
5 June 2026Leerink PartnersMaintainsOutperform—
4 May 2026BarclaysMaintainsOverweight—
4 May 2026Truist SecuritiesReiteratesHold—
1 May 2026BTIGMaintainsBuy—
1 May 2026Canaccord GenuityMaintainsBuy—
1 May 2026Evercore ISI GroupMaintainsOutperform—
1 May 2026JP MorganMaintainsOverweight—
1 May 2026NeedhamMaintainsBuy—
1 May 2026Wells FargoMaintainsOverweight—
15 Apr 2026Truist SecuritiesMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SYK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SYK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Stryker Corp. (SYK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
36.0×

Cheaper than 22% of US stocks

Price / sales
5.1×

Cheaper than 25% of US stocks

Price / book
5.7×

Cheaper than 19% of US stocks

EV / EBITDA
19.4×

Cheaper than 17% of US stocks

Growth & margins
Revenue growth (YoY)
9.4%

Higher than 51% of US stocks

Earnings growth (YoY)
44.3%

Higher than 73% of US stocks

Gross margin
68.3%

Higher than 81% of US stocks

Operating margin
27.0%

Higher than 85% of US stocks

Net margin
14.4%

Higher than 77% of US stocks

Returns & dividend
Return on equity
16.5%

Higher than 77% of US stocks

Return on assets
8.2%

Higher than 88% of US stocks

Dividend yield
1.0%

Higher than 24% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SYK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SYKStryker Corp.$130.8B
74
MDTMedtronic PLC$116.1B
83
ABTAbbott Laboratories$193.5B
53
BSXBoston Scientific Corp.$76.6B
57
EWEdwards Lifesciences Corp.$53.3B
91
DXCMDexCom, Inc.$35.3B
98
GEHCGE Healthcare Technologies, Inc.$33.6B
64

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Stryker Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SYK news & analysis

SYK Stock Gains 3.8% Since March-End: What's Driving the Uptrend?

Zacks Investment Research · 14 Aug 2026positive

Shares of Stryker (SYK) gained 3.8% since the end of March, according to Zacks Investment Research. The uptrend is attributed to momentum in Mako robotics, hospital capital demand, and international growth.

Why it matters — For SYK watchers, the report points to continued demand for the company's robotics platform and broader capital spending as contributing factors behind recent share-price gains.

Is SYK Worth Buying as Growth Improves but Execution Risks Persist?

Zacks Investment Research · 13 Aug 2026neutral

Zacks Research published a balanced analysis noting that Stryker's growth, margins and product pipeline are improving, while risks from cyber costs, supply constraints and acquisition execution remain elevated.

Why it matters — SYK watchers would care because the analysis highlights both the company's improving fundamentals and the key execution headwinds that could affect near-term performance.

Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?

Zacks Investment Research · 13 Aug 2026neutral

Stryker regained momentum in Q2, but its ability to meet full-year guidance depends on production output, converting its backlog, and managing cybersecurity and supply-chain risks.

Why it matters — The article highlights key operational challenges that could determine whether Stryker's second-half performance matches its Q2 recovery.

Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?

Zacks Investment Research · 13 Aug 2026positive

Stryker shares rose 13.6% over three months, driven by improving sales, margins, and production. The article notes that further gains could be challenged by execution risks and the stock's premium valuation relative to peers.

Why it matters — A SYK watcher would care because the rally signals improving operational performance, but the caution about valuation and execution highlights potential headwinds to monitor going forward.

PBH or SYK: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 12 Aug 2026neutral

Zacks Investment Research published a comparison between Prestige Consumer Healthcare (PBH) and Stryker (SYK), evaluating which of the two medical-products stocks offers the better value opportunity at this time.

Why it matters — Stryker investors tracking valuation trends may find the analysis useful for benchmarking SYK against a peer in the medical-products space.

FAQ

Frequently asked questions about SYK stock

What is the SYK stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Stryker Corp. have a median 12-month price target of $381, with estimates ranging from $315 to $465. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SYK stock a buy right now?

Of the 28 analysts covering Stryker Corp., 23 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stryker Corp. 74 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SYK?

As at 13 Aug 2026, Stryker Corp. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (95 of 100).

Will SYK stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +12.3% from the last close, and Ticker Nerd's factor model ranks Stryker Corp. 74 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SYK stock forecast for 2030?

No analyst covering Stryker Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SYK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $315 to $465 over the next 12 months.

How has SYK stock performed over the past year?

Stryker Corp. returned -9.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Stryker Corp. do?

Stryker Corporation is a medical technology company that develops and markets products used in hospitals, surgery centers, and other healthcare settings. Its current portfolio spans MedSurg, Neurotechnology, and Orthopaedics, with offerings that include surgical equipment, endoscopy systems, patient handling and emergency care devices, neurosurgical and neurovascular products, spinal devices, and implants for joint replacement and trauma procedures.

What is the latest news on SYK?

The most recent item we track (Zacks Investment Research, 14 Aug 2026): "SYK Stock Gains 3.8% Since March-End: What's Driving the Uptrend?". Shares of Stryker (SYK) gained 3.8% since the end of March, according to Zacks Investment Research. The uptrend is attributed to momentum in Mako robotics, hospital capital demand, and international growth.

Company

About Stryker Corp.

Stryker Corporation is a medical technology company that develops and markets products used in hospitals, surgery centers, and other healthcare settings. Its current portfolio spans MedSurg, Neurotechnology, and Orthopaedics, with offerings that include surgical equipment, endoscopy systems, patient handling and emergency care devices, neurosurgical and neurovascular products, spinal devices, and implants for joint replacement and trauma procedures. The company also provides technologies and equipment designed to support clinicians in performing procedures more efficiently and to improve patient care across a wide range of specialties. Stryker Corporation serves healthcare professionals and institutions worldwide, making it a significant supplier in the global medical devices market. Founded in 1946 and headquartered in Portage, Michigan, Stryker remains focused on medical technologies that are widely used in surgical, orthopedic, and neuro specialty care.

CEO Mr. Kevin A. Lobo · 56,000 employees · United States · https://www.stryker.com